Literature DB >> 15925080

Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).

Raymond C Rosen1, Francois Giuliano, Culley C Carson.   

Abstract

Sexuality is an essential aspect of a couple's relationship and has a significant impact on life satisfaction. Benign prostatic hyperplasia (BPH) is a condition that commonly affects older men and is often associated with lower urinary tract symptoms (LUTS) and sexual dysfunction. Men with moderate-to-severe LUTS are at increased risk for sexual dysfunction, including moderate-to-severe erectile dysfunction (ED), ejaculatory dysfunction (EjD), and hypoactive desire (HD). The results of several recent large-scale studies have shown a consistent and strong relationship between LUTS and both ED and EjD. It appears that the pathophysiological mechanisms of LUTS and the related prostatic enlargement of BPH as well as certain treatments for this condition may have an impact on both the erection and ejaculation components of the sexual response. Validated questionnaires that assess sexual function provide clinicians with valuable information to help guide treatment selection decisions. Effective medical therapies for LUTS associated with BPH include alpha(1)-adrenergic receptor antagonists (i.e., alfuzosin, doxazosin, tamsulosin, and terazosin) and 5alpha-reductase inhibitors (i.e., finasteride and dutasteride). The side effects of these medications, including sexual dysfunction, are important distinguishing features. The successful management of patients with LUTS associated with BPH should include assessments of sexual function and monitoring of medication-related sexual side effects. For men with LUTS and sexual dysfunction, an appropriate integrated management approach, based on each patient's symptoms and outcome objectives, is warranted.

Entities:  

Mesh:

Year:  2005        PMID: 15925080     DOI: 10.1016/j.eururo.2004.12.013

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  54 in total

1.  Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men.

Authors:  Sean A Martin; Matthew T Haren; Villis R Marshall; Kylie Lange; Gary A Wittert
Journal:  World J Urol       Date:  2010-10-21       Impact factor: 4.226

2.  Clinical efficacy of combination therapy with an alpha blocker and low-dose sildenafil on post-therapy lower urinary tract symptoms after low-dose-rate brachytherapy for prostate cancer.

Authors:  Young Dong Yu; Moon Hyung Kang; Chang Il Choi; Hyun Soo Shin; Jong Jin Oh; Dong Soo Park
Journal:  World J Urol       Date:  2016-02-11       Impact factor: 4.226

Review 3.  Lower urinary tract disease: what are we trying to treat and in whom?

Authors:  Jeremy P W Heaton
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 4.  [Medical combination therapy in LUTS suggestive of BPH].

Authors:  K Höfner; M Oelke
Journal:  Urologe A       Date:  2009-03       Impact factor: 0.639

Review 5.  Erectile Dysfunction and Lower Urinary Tract Symptoms.

Authors:  Cosimo De Nunzio; Riccardo Lombardo; Giorgia Tema; Andrea Tubaro
Journal:  Curr Urol Rep       Date:  2018-06-01       Impact factor: 3.092

6.  Prevalence estimates for lower urinary tract symptom severity among men in Uganda and sub-Saharan Africa based on regional prevalence data.

Authors:  Francis Bajunirwe; Lynn Stothers; Jonathan Berkowitz; Andrew J Macnab
Journal:  Can Urol Assoc J       Date:  2018-06-08       Impact factor: 1.862

7.  Urodynamic effects of once-daily tadalafil in men with LUTS secondary to clinical BPH.

Authors:  Alex Gomelsky; Roger R Dmochowski
Journal:  Curr Urol Rep       Date:  2010-07       Impact factor: 3.092

Review 8.  Obstruction-induced alterations within the urinary bladder and their role in the pathophysiology of lower urinary tract symptomatology.

Authors:  Christos Komninos; Iraklis Mitsogiannis
Journal:  Can Urol Assoc J       Date:  2014-07       Impact factor: 1.862

9.  Effectiveness of doxazosin on erectile dysfunction in patients with lower urinary tract symptoms.

Authors:  Gokhan Faydaci; Ugur Kuyumcuoglu; Bilal Eryildirim; Alper Aktas; Fatih Tarhan; Murat Tuncer
Journal:  Int Urol Nephrol       Date:  2010-11-04       Impact factor: 2.370

Review 10.  Place of overactive bladder in male lower urinary tract symptoms.

Authors:  Osamu Yamaguchi; Ken Aikawa; Keiichi Shishido; Masanori Nomiya
Journal:  World J Urol       Date:  2009-12       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.